


# Lucentis 0.5mg Prefilled Syringe Analysis (PFS)

Lucentis 0.5mg PFS contributed [REDACTED] increase vs trend in total Lucentis 0.5mg sales 12M post launch



Post-Launch 12M Actual (\$ Sales)	Post-Launch 12M Trend (\$ Sales)	Difference (Post-Launch Actual Sales - Post-Launch Trend Sales)	wAMD Contribution (Difference / wAMD Contribution)	Impact Difference / Post-Launch Actual (\$ Sales)
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

Source : IQVIA NPA Monthly thru Sep 19, Pre Launch 12M - Feb 15 to Jan 17, Post Launch 12M - Mar 17 to Feb 18  
 Contribution of wAMD : IQVIA Claims thru Aug 19  
<https://www.roche.com/investors/updates/inv-update-2016-10-17.htm>

Commercial Acceleration



17-00195220-00 | 0000196116-1010079-01 | 029015 | 1/40 | 1/20